Your new experience awaits. Try the new design now and help us make it even better

STUDY PROTOCOL article

Front. Neurol.

Sec. Stroke

Volume 16 - 2025 | doi: 10.3389/fneur.2025.1665032

Efficacy of Endovascular Treatment for Patients with Acute Large Vessel Occlusion Stroke from the Western Sichuan Plateau and Machine Learning Prediction Models: A Prospective Study Protocol

Provisionally accepted
  • 1North Sichuan Medical College, Nanchong, China
  • 2Department of Neurology, The Affiliated Hospital, Southwest Medical University, Luzhou, China
  • 3Department of Neurology, Ya’an People's Hospital, Ya’an, China
  • 4Sichuan Agricultural University, Ya'an, China

The final, formatted version of the article will be published soon.

Objectives: Stroke is the second leading cause of death and the third leading cause of disability among non-communicable diseases globally. The prevalence, incidence, and mortality rates of stroke are higher in high-altitude regions compared to lowland areas. However, compared to plain areas, the efficacy of endovascular therapy for large vessel occlusive acute ischemic stroke (LVO-AIS) in high-altitude regions remains unclear. Methods and Design: This study is a multicenter, prospective, endpoint-blinded cohort study. From January 2025 to December 2027, a total of 1,052 patients with acute large vessel occlusion ischemic stroke (LVO-AIS) from the Western Sichuan Plateau will be prospectively enrolled, including those who receive endovascular treatment and those who do not. Baseline characteristics and endovascular treatment details will be documented. Treatment decisions are guided by clinical practice guidelines, taking into account high-altitude real-world constraints such as patient or proxy refusal and delays in interhospital transfer. Medical records will be established for each patient, and a 180-day follow-up will be conducted. The primary outcome was the proportion of patients achieving functional independence [modified Rankin scale(mRS) range from 0 to 2] at 90 days. The secondary outcomes included the mRS score at 90 days, early neurological improvement rate [defined as a National Institutes of Health Stroke Scale (NIHSS) score of 0-2 or a reduction of ≥8 points from baseline within 24 hours of enrollment], changes in NIHSS scores between day 7±1 or discharge and baseline, quality of life as assessed by the five-level EuroQol five-dimensional questionnaire at 90 days, and cognitive function at 180 days will be assessed using mini-mental state examination and montreal cognitive assessment scores. Imaging outcomes will include the rate of successful reperfusion (defined as a modified Thrombolysis in Cerebral Infarction score ≥2b) and infarct volume measured within 5–7 days. Statistical analysis and fused optimized multimodal learning were blinded to the group assignments. Conclusion: This study aims to evaluate the efficacy of endovascular treatment compared with standard medical therapy in patients with LVO-AIS in the Western Sichuan Plateau and to develop an artificial intelligence–based prognostic model to refine treatment strategies for this and other high-altitude regions.

Keywords: Acute ischemic stroke, study protocol, high-altitude, endovascular treatment, cohort study, machine-learning

Received: 14 Jul 2025; Accepted: 21 Aug 2025.

Copyright: © 2025 Duan, Hu, Luo, Zhang, Liu, Li, Xiong, Duan, Niu, Huang, chen and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Jian Wang, Department of Neurology, The Affiliated Hospital, Southwest Medical University, Luzhou, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.